US5185246A - Method for semen analysis employing membrane separation - Google Patents
Method for semen analysis employing membrane separation Download PDFInfo
- Publication number
- US5185246A US5185246A US07/685,439 US68543991A US5185246A US 5185246 A US5185246 A US 5185246A US 68543991 A US68543991 A US 68543991A US 5185246 A US5185246 A US 5185246A
- Authority
- US
- United States
- Prior art keywords
- membrane
- semen
- seminal plasma
- well
- pbs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000000926 separation method Methods 0.000 title claims abstract description 22
- 238000009612 semen analysis Methods 0.000 title description 3
- 210000000582 semen Anatomy 0.000 claims abstract description 71
- 102000004190 Enzymes Human genes 0.000 claims abstract description 13
- 108090000790 Enzymes Proteins 0.000 claims abstract description 13
- 239000011148 porous material Substances 0.000 claims abstract description 8
- 238000003556 assay Methods 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000003992 Peroxidases Human genes 0.000 claims description 4
- 230000000469 anti-sperm effect Effects 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 4
- 102100026041 Acrosin Human genes 0.000 abstract description 13
- 108090000107 Acrosin Proteins 0.000 abstract description 13
- 239000002245 particle Substances 0.000 abstract 1
- 239000002953 phosphate buffered saline Substances 0.000 description 27
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 26
- 238000012360 testing method Methods 0.000 description 13
- 229930091371 Fructose Natural products 0.000 description 12
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 12
- 239000005715 Fructose Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000005018 casein Substances 0.000 description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 6
- 235000021240 caseins Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000609499 Palicourea Species 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- -1 i.e. Proteins 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DEOKFPFLXFNAON-UHFFFAOYSA-N N-α-Benzoyl-DL-arginine 4-nitroanilide hydrochloride Chemical compound Cl.C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(CCCN=C(N)N)NC(=O)C1=CC=CC=C1 DEOKFPFLXFNAON-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229940096329 human immunoglobulin a Drugs 0.000 description 2
- 229940098197 human immunoglobulin g Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000045365 Microporus <basidiomycete fungus> Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229940094342 human immunoglobulin m Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/147—Microfiltration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
Definitions
- Semen consists of a mixture of particulates including spermatozoa, other cells and a liquid portion, which comprises proteins, hormones and other dissolved or suspended molecules collectively known as seminal plasma. Seminal analysis and evaluation is a routine diagnostic procedure that is carried out in connection with fertility studies. Specimens should be analyzed within two hours of collection which places a time constraint on the analytical technique.
- the analysis of semen involves the separation of the solid content from the liquid material. This has been done in the prior art by mechanical centrifugation using conventional techniques and an applied force of 500 to 1000 g for 10 to 30 minutes.
- the difficulty in separating the contents of semen using this type of a procedure is that the separated seminal plasma must be manually withdrawn from the centrifuge container before removal of the pellet which contains the separated spermatozoa. The pellet requires further washing to remove traces of the seminal plasma and resuspension in a suitable liquid.
- Analyses which require the separation of spermatozoa from seminal plasma include the determination of acrosin (Mohsenian et al., 1982 Fertil.
- the centrifugation which is used in the separations that are required for seminal analyses is time consuming and difficult for running multiple samples.
- the required sample size of about 1.0 ml makes it impossible to analyze the same semen sample that is used for in vitro fertilization or artificial insemination.
- the present invention is concerned with an improved method for the separation of seminal plasma from the particulates in semen.
- the improved method comprises separating seminal plasma from semen by means of a membrane which allows only the seminal plasma to pass and retains particulates on the membrane surface. Synthetic hydrophilic, microporus membranes are preferred because they are inert towards semen. If only the spermatozoa are going to be analysed, then the seminal plasma is simply removed and discarded.
- the filtrate from the semen can preferably be collected into 96 individual wells of a 96 multi-well non-porous plate using a collector such as the transfer guide available from Millipore or by positioning the plate immediately beneath the membrane plate and then applying a vacuum.
- a collector such as the transfer guide available from Millipore or by positioning the plate immediately beneath the membrane plate and then applying a vacuum.
- the invention also provides a novel means for the determination of acrosin and for the determination of sperm antibodies.
- Some advantages of the present invention associated with no centrifugation are 1) faster assays, 2) easier handling of large numbers of samples, 3) inexpensive, 4) no loss of either part of the sample, and 5) miniaturization of current assay formats to reduce sample and reagent volumes.
- the use of a 96-well membrane plate format can take advantage of recent improvements in multi-sample handling such as multichannel pipettors and 96-well plate reader spectrophotometers, colorimeters, luminometers, and fluorimeters and their respective data reduction capabilities.
- the separation of seminal plasma is achieved by (a) applying a semen sample to the upper surface of a membrane; and (b) collecting the seminal plasma at the lower surface of said membrane.
- the process of the invention may be used in the analysis of semen from humans, domesticated animals and animals normally found in zoological collections. Generally, it is preferred to dilute the semen sample with an isotonic buffer solution such as phosphate buffer solution prior to separation. Dilutions of 1:2 to 1:50 of semen in isotonic buffer solution and more preferably from 1:10 to 1:20 may be utilized. The use of a diluent facilitates the separation of particulates from the seminal plasma.
- the membrane is mounted in a multiwell membrane plate of the type disclosed in United States Patents Nos. 4,427,415; 4,734,192; and 4,797,259, which are incorporated by reference.
- polymeric membranes having a porosity which is sufficient to retain particulates while allowing the plasma to pass through the membrane.
- the polymeric membrane as opposed to an ordinary paper filter, will allow fluid to be retained in each well until vacuum pressure is applied. With an ordinary paper filter, liquid will drip through from the force of gravity alone. The failure to retain fluid would prevent the use of the well as the reaction vessel for an assay.
- the material which the polymer is made of is not critical, but it should be a low protein binding material.
- a low protein binding material is one that does not absorb a sufficient amount of a protein, i.e., albumin or an immunoglobulin which would interfere with the subsequent assay of the spermatozoa.
- Polycarbonates, polyamides or polyvinylidene difluoride may be utilized for making the membrane using conventional technique.
- a useful average pore size diameter in the membrane is about 0.15-3.0 um, but the precise pore size is not critical and may be varied depending on the degree of separation that is desired. Membranes with smaller diameter pores may tend to clog and retard flow rates and those with average pore diameter of up to about 3.0 um will exhibit higher flow rates.
- the thickness of the membrane is not critical and membranes having a thickness of from 1 to 50 microns may be used in combination with a conventional porous support structure.
- vacuum it is preferred to apply vacuum to the membrane using the vacuum generated by a flow of water, a portable vacuum pump or an external vacuum source to facilitate the filtration step.
- the spermatozoa may be analyzed directly on the membrane without further manipulative steps.
- the use of a multiwell membrane plate provides discrete samples that may be subjected to direct analysis without further manipulation.
- the novel acrosin assay of the invention comprises (a) the separation of the seminal plasma using a membrane and (b) the determination of acrosin activity of spermatozoa using a colorimetric method of analysis that is based on a chromogenic substance.
- the hydrolysis of a colorless substrate quantitatively produces a highly colored soluble product which provides a means for measuring the enzyme activity.
- an amino acid containing substrate such as N-benzoyl-DL-arginine-p-nitroanilide hydrochloride or N-benzyl-oxycarbonyl-L-phenyl-alanyl-L-valyl-L-arginine-p-nitroanilide hydrobromide can be used.
- trypsin which is a different serine protease having hydrolytic activity similar to that of acrosin can be used as a positive control. For this reason, a suitable formulation of trypsin may be included in kits for the determination of acrosin.
- the detection of sperm antibodies comprises (a) the separation of seminal plasma from particulates, (b) contacting the particulates with alkaline phosphatase or another appropriate enzyme such as peroxidase, glucose oxidase, or urease conjugated to an anti-immunoprotein such as an immunoglobulin or another protein such as protein A or protein G which will bind to immunoglobulin and (c) spectro-photometrically or using some other detecting system such as a system which is based on fluorescence, chemiluminescence, and the like determining the amount of antibody which binds to the sperm by measurement of the antibody bound alkaline phosphatase-anti-immunoglobulin.
- alkaline phosphatase or another appropriate enzyme such as peroxidase, glucose oxidase, or urease conjugated to an anti-immunoprotein such as an immunoglobulin or another protein such as protein A or protein G which will bind to immunoglobulin
- the seminal plasma which can be collected into individual wells of a 96-well plate may be analyzed directly.
- the detection of fructose comprises (a) the separation of seminal plasma from particulates, (b) contacting the seminal plasma with zinc sulfate and sodium hydroxide solutions, (c) separating the solution produced in step (b) from particulates using a second membrane plate, (d) contacting the solution separated in step (c) with indol reagent and concentrated hydrochloric acid, and (e) spectrophotometrically determining the amount of fructose present in seminal plasma.
- kits for semen analysis will include a membrane plate and a reagent system suitable for the determination of one or more constituents of semen. These components may be selected according to the particular test which is to be carried out.
- the method for the determination of acrosin activity in a semen sample can be practiced by using a kit comprising:
- a suitable membrane plate such as a 96-well membrane plate
- washing buffer such as phosphate buffered saline (PBS);
- detergent solution such as an ethoxylated alcohol, i.e., octyl phenoxyl polyethoxy ethanol;
- enzyme substrate such as a chromogenic arginine substrate
- the method for the determination of anti-sperm antibodies can be practiced by using a kit comprising:
- washing buffer such as PBS
- the method for the determination of fructose in seminal fluid can be practiced by using a kit comprising:
- the reagent systems for many tests are known and may be selected according to the specific assay protocol.
- a fresh human semen sample in a cup is obtained from a donor.
- the sample is allowed to liquefy for about 30 minutes at room temperature.
- An aliquot is removed for counting.
- the count is 27 ⁇ 10 6 cells per ml.
- a series of dilutions is made using phosphate buffered saline, pH 7.4 (PBS).
- the dilutions are 1:2; 1:4; 1:8; and 1:16 in PBS.
- One hundred microliters of each dilution is pipetted into the well of a 1.2 micron pore size 96 well membrane plate where the wells have a capacity of about 400 ul and the membrane filter area is 0.28 cm 2 Vacuum is applied from a water stream for about 60 seconds. There is virtually no detectable separation of the 1:2 dilution; the seminal plasma is readily separated from the other dilutions.
- a fresh semen sample in a cup is obtained from a donor. The sample is allowed to liquefy for about 30 minutes room temperature. An aliquot is removed for counting. Cell number is determined to be 78 ⁇ 10 6 cells/ml
- a series of semen dilutions are prepared using phosphate-buffered saline, pH 7.4 (PBS consists of 1440 mg/L KH 2 PO 4 +90 g/L NaCl +7950 mg/L Na 2 HPO 4 in water, available from Whittaker M.A. Bioproducts). One hundred ul of each dilution is pipetted into the well of a 1.2 ⁇ m membrane plate from Pall Corp. (product no. SM120L). Controls are no semen, PBS alone. The plate is placed on a vacuum manifold (from Isolab).
- Vacuum is applied (house vacuum) so as to remove all liquid in the wells without breaking the membrane. About 400 ul PBS is added to each well with the vacuum on. This washing method is repeated. When all the wells are completely free of liquid, the vacuum is turned off. The bottom of the wells are blotted with absorbent paper.
- the presence of sperm-reactive antibodies in test antiserum is assayed on control spermatozoa.
- a fresh semen sample in a cup is obtained from a donor. The sample is allowed to liquefy for about 30 minutes room temperature. An aliquot is removed for counting. The cell number is determined to be 96 ⁇ 10 6 cells/ml
- the semen is diluted using PBS by adding 100 ul of semen to 1900 ul of PBS. Then 100 ul of the diluted semen is pipetted into the wells of a 0.22 um Durapore (product no. STGV 09610) plate from illipore. The plate is placed on a vacuum manifold (from Isolab). Vacuum is applied so as to remove all liquid in the wells.
- the substrate is 5 mg para-nitrophenyl phosphate dissolved in 5 ml buffer [26.2 g diethanolamine dissolved in 250 ml water, pH 9.8, with 1 ml magnesium chloride (2.03 g MgCl 2 ⁇ 6H 2 O in 20 ml water)]. After 15 minutes incubation, the contents of each well are removed and read in a spectrophotometer at 405 nm wavelength. The results are shown below:
- a fresh semen sample in a cup is obtained from a donor The sample is allowed to liquify for about 30 min. room temperature. An aliquot is diluted 1:50 with PBS (100 ul semen +4900 ul PBS). Then 200 ul of the diluted semen is pipetted into the wells of a 1.2 um membrane plate from Pall Corp. (product no. SM120L). The plate is placed on a vacuum manifold (from Isolab). Vacuum is applied so as to remove all liquid in the wells and collect individual filtrates into a 96-multiwell plastic plate positioned immediately beneath the membrane plate. Then 60 ul of 1.8% (w/v) ZnSO 4 ⁇ 7H 2 O are added to each well.
- the plate is gently shaken to mix. 40 ul of 0.1 M NaOH are added and the plate is gently shaken to mix. The plate and contents are incubated 15 min. at room temperature. The contents are transferred to a second 1.2 um membrane plate and vacuum is applied so as to remove all liquid in the wells and collect individual filtrates into a 96-multiwell plastic plate positioned immediately beneath the membrane plate. A 250 ul portion of each filtrate is transferred to glass test tubes with glass stoppers. For controls, 250 ul of each working fructose standard which are 0.28 mM and 0.14 mM fructose diluted up fresh from a frozen stored stock of 2.8 mM fructose are used with 250 ul distilled water as a reagent blank.
- indol reagent is made by first dissolving 200 mg benzoic acid in 100 ml water at 60° C., then adding 25 mg indol and filtering the solution before stirring at 4° C. Then 2.5 ml concentrated HCl are added to each test tube.
- the test tubes are stoppered and incubated 20 min. at 50° C. They are cooled in ice water to room temperature and the O.D. is read at 470 nm.
- the fructose concentration (mmol/L) in seminal plasma is calculated according to the equation:
- F mean fructose standard factor according to the formula: ##EQU1## where s 1 and s 2 are the mean optical density readings for the 0.14 mM and 0.28 mM fructose standards, respectively; 75 is the dilution factor of seminal plasma.
- spermreactive antibodies in test antiserum is assayed on control spermatozoa.
- a fresh semen sample in a cup is obtained from a donor. The sample is allowed to liquify for about 30 minutes room temperature. An aliquot is removed from counting. The cell number is determined to be 287 ⁇ 10 6 cells/ml
- the semen is diluted using 0.5% casein in PBS by adding 100 ul of semen to 500 ul of 0.5% casein in PBS. Then 25 ul of the diluted semen is pipetted into the wells of a 0.45 um Loprodyne plate (product number SM3000L5) from Pall.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Water Supply & Treatment (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A method is disclosed for the separation of seminal plasma from semen by means of a membrane. The invention also includes a method for the determination of enzymes such as acrosin and other components of semen. More specifically the membrane has a specific pore size and traps particles which can be immuno-tested.
Description
This is a Continuation-in-Part of application Ser. No. 07/339,505, filed Apr. 17, 1989, now U.S. Pat. No. 5,028,526.
Semen consists of a mixture of particulates including spermatozoa, other cells and a liquid portion, which comprises proteins, hormones and other dissolved or suspended molecules collectively known as seminal plasma. Seminal analysis and evaluation is a routine diagnostic procedure that is carried out in connection with fertility studies. Specimens should be analyzed within two hours of collection which places a time constraint on the analytical technique.
The analysis of semen involves the separation of the solid content from the liquid material. This has been done in the prior art by mechanical centrifugation using conventional techniques and an applied force of 500 to 1000 g for 10 to 30 minutes. The difficulty in separating the contents of semen using this type of a procedure is that the separated seminal plasma must be manually withdrawn from the centrifuge container before removal of the pellet which contains the separated spermatozoa. The pellet requires further washing to remove traces of the seminal plasma and resuspension in a suitable liquid. Analyses which require the separation of spermatozoa from seminal plasma include the determination of acrosin (Mohsenian et al., 1982 Fertil. Steril., 37:223-229; Goodpasture et al., J. Reprod. Fertil., 1981, 63:397-405; Goodpasture et al., J. Androl. 1982, 3:151-156; Goodpasture et al., J. Androl. 1987, 8:267-271; Schill., Fertil. Steril. 1975, 26:711-720; Schill et al., Int. J. Fertil. 1974, 19:217-227; Zaneveld et al., J. Reprod. Fertil. 1973, 32:525-529, all of which are incorporated by reference); hyaluronidase; acid phosphatases; β-galactosidase; -N-acetylgalactosaminidase; β-galactosidase (Mack et al. 1983, Biol. Reprod., 28:1032-1042) and anti-sperm antibodies (WHO Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucous Interaction, 1987, Cambridge Univ. Press NY, NY, which is incorporated by reference). Seminal plasma is usually used for the determination of zinc, citric acid, fructose (all described in WHO Laboratory Manual), hormones such as relaxin (Weiss et al. 1986, Am. J. Obstetr. Gynecol. 154: 749-755) or metabolites such as glycerophosphocholine (Chap et al. 1988, Clin. Chem. 34: 106-109).
The centrifugation which is used in the separations that are required for seminal analyses is time consuming and difficult for running multiple samples. The required sample size of about 1.0 ml makes it impossible to analyze the same semen sample that is used for in vitro fertilization or artificial insemination.
Aside from the drawbacks of centrifugation, several assays for anti-sperm antibodies also have weaknesses. These assays use 1) agglutination (reviewed in R. Bronson et al. Fertil. Steril. (1984) 42: 171-183) which is very subjective and may give false negative and false positive results, 2) microscopic examination and counting of beads on the sperm surface (Bronson et al. 1982. Arch. Androl. 9: 61) which is labor-intensive and somewhat subjective, or 3) enzyme immunoassay of immobilized sonicated sperm including both intracellular and cell-surface antigens (W. Harel and D. Nelken. 1985. Am. J. Reprod. Immunol. Microbio. 8:137) which can give false-positive and false-negative results.
The present invention is concerned with an improved method for the separation of seminal plasma from the particulates in semen. The improved method comprises separating seminal plasma from semen by means of a membrane which allows only the seminal plasma to pass and retains particulates on the membrane surface. Synthetic hydrophilic, microporus membranes are preferred because they are inert towards semen. If only the spermatozoa are going to be analysed, then the seminal plasma is simply removed and discarded. If the seminal plasma is going to be analyzed, then the filtrate from the semen can preferably be collected into 96 individual wells of a 96 multi-well non-porous plate using a collector such as the transfer guide available from Millipore or by positioning the plate immediately beneath the membrane plate and then applying a vacuum. The invention also provides a novel means for the determination of acrosin and for the determination of sperm antibodies.
It could not have been predicted prior to testing semen on a polymeric membrane surface that the membrane would be unreactive with any component in semen. In addition, it could not have been predicted whether or not the polymeric membrane surface could denature any of the enzymes in semen, interfere chemically with the various semen analysis assays, destroy the cell integrity, react nonspecifically with antibodies or tie up any binding sites that would interfere with an antibody assay.
Some advantages of the present invention associated with no centrifugation are 1) faster assays, 2) easier handling of large numbers of samples, 3) inexpensive, 4) no loss of either part of the sample, and 5) miniaturization of current assay formats to reduce sample and reagent volumes. Furthermore, the use of a 96-well membrane plate format can take advantage of recent improvements in multi-sample handling such as multichannel pipettors and 96-well plate reader spectrophotometers, colorimeters, luminometers, and fluorimeters and their respective data reduction capabilities.
Accordingly, it is a primary object of this invention to provide a novel means for the separation of seminal plasma from particulates in semen.
It is also an object of this invention to provide a novel method for the separation of seminal plasma from particulates in semen which avoids the use of a centrifuge and the associated mechanical manipulative steps.
It is also an object of this invention to provide a rapid separation technique which may be applied to very small samples.
It is also an object of this invention to provide a separation technique that permits the determination of a plurality of components using the same sample rather than multiple samples.
It is also an object of this invention to provide a separation technique that permits the simultaneous determination of a plurality of samples rather than a small number of samples that must be processed sequentially.
It is also an object of this invention to provide a novel method for the determination of acrosin activity in spermatozoa.
It is also an object of this invention to provide a novel method for the determination of sperm antibodies.
These and other objects will become apparent from the detailed description of the invention.
The separation of seminal plasma is achieved by (a) applying a semen sample to the upper surface of a membrane; and (b) collecting the seminal plasma at the lower surface of said membrane.
The process of the invention may be used in the analysis of semen from humans, domesticated animals and animals normally found in zoological collections. Generally, it is preferred to dilute the semen sample with an isotonic buffer solution such as phosphate buffer solution prior to separation. Dilutions of 1:2 to 1:50 of semen in isotonic buffer solution and more preferably from 1:10 to 1:20 may be utilized. The use of a diluent facilitates the separation of particulates from the seminal plasma. Preferably, the membrane is mounted in a multiwell membrane plate of the type disclosed in United States Patents Nos. 4,427,415; 4,734,192; and 4,797,259, which are incorporated by reference. Generally, it is preferred to employ polymeric membranes having a porosity which is sufficient to retain particulates while allowing the plasma to pass through the membrane. The polymeric membrane, as opposed to an ordinary paper filter, will allow fluid to be retained in each well until vacuum pressure is applied. With an ordinary paper filter, liquid will drip through from the force of gravity alone. The failure to retain fluid would prevent the use of the well as the reaction vessel for an assay. The material which the polymer is made of is not critical, but it should be a low protein binding material. A low protein binding material is one that does not absorb a sufficient amount of a protein, i.e., albumin or an immunoglobulin which would interfere with the subsequent assay of the spermatozoa. Polycarbonates, polyamides or polyvinylidene difluoride may be utilized for making the membrane using conventional technique. A useful average pore size diameter in the membrane is about 0.15-3.0 um, but the precise pore size is not critical and may be varied depending on the degree of separation that is desired. Membranes with smaller diameter pores may tend to clog and retard flow rates and those with average pore diameter of up to about 3.0 um will exhibit higher flow rates. The thickness of the membrane is not critical and membranes having a thickness of from 1 to 50 microns may be used in combination with a conventional porous support structure.
It is preferred to apply vacuum to the membrane using the vacuum generated by a flow of water, a portable vacuum pump or an external vacuum source to facilitate the filtration step.
After the separation of the seminal plasma, the spermatozoa may be analyzed directly on the membrane without further manipulative steps. The use of a multiwell membrane plate provides discrete samples that may be subjected to direct analysis without further manipulation.
The novel acrosin assay of the invention comprises (a) the separation of the seminal plasma using a membrane and (b) the determination of acrosin activity of spermatozoa using a colorimetric method of analysis that is based on a chromogenic substance. The hydrolysis of a colorless substrate quantitatively produces a highly colored soluble product which provides a means for measuring the enzyme activity. For example, an amino acid containing substrate such as N-benzoyl-DL-arginine-p-nitroanilide hydrochloride or N-benzyl-oxycarbonyl-L-phenyl-alanyl-L-valyl-L-arginine-p-nitroanilide hydrobromide can be used. Because acrosin is not readily available, trypsin which is a different serine protease having hydrolytic activity similar to that of acrosin can be used as a positive control. For this reason, a suitable formulation of trypsin may be included in kits for the determination of acrosin.
The detection of sperm antibodies comprises (a) the separation of seminal plasma from particulates, (b) contacting the particulates with alkaline phosphatase or another appropriate enzyme such as peroxidase, glucose oxidase, or urease conjugated to an anti-immunoprotein such as an immunoglobulin or another protein such as protein A or protein G which will bind to immunoglobulin and (c) spectro-photometrically or using some other detecting system such as a system which is based on fluorescence, chemiluminescence, and the like determining the amount of antibody which binds to the sperm by measurement of the antibody bound alkaline phosphatase-anti-immunoglobulin.
Alternately, after the separation of the spermatozoa, the seminal plasma which can be collected into individual wells of a 96-well plate may be analyzed directly.
The detection of fructose comprises (a) the separation of seminal plasma from particulates, (b) contacting the seminal plasma with zinc sulfate and sodium hydroxide solutions, (c) separating the solution produced in step (b) from particulates using a second membrane plate, (d) contacting the solution separated in step (c) with indol reagent and concentrated hydrochloric acid, and (e) spectrophotometrically determining the amount of fructose present in seminal plasma.
Generally, kits for semen analysis will include a membrane plate and a reagent system suitable for the determination of one or more constituents of semen. These components may be selected according to the particular test which is to be carried out. The method for the determination of acrosin activity in a semen sample can be practiced by using a kit comprising:
(a) a suitable membrane plate, such as a 96-well membrane plate;
(b) washing buffer, such as phosphate buffered saline (PBS);
(c) detergent solution, such as an ethoxylated alcohol, i.e., octyl phenoxyl polyethoxy ethanol;
(d) enzyme substrate, such as a chromogenic arginine substrate; and
(e) a reference amount of trypsin or another protease with acrosin-like activity.
The method for the determination of anti-sperm antibodies can be practiced by using a kit comprising:
(a) a 96-well membrane plate;
(b) washing buffer, such as PBS;
(c) given amounts of labeled anti-human immunogobulins A, G, and M using alkaline phosphatase or any other suitable enzyme as the label;
(d) enzyme substrate; and
(e) positive and negative serum controls.
The method for the determination of fructose in seminal fluid can be practiced by using a kit comprising:
(a) a 96-well membrane plate and a 96-well plate;
(b) given amounts of zinc sulfate, sodium hydroxide, indol reagent and concentrated hydrochloric acid; and
(c) fructose standards.
The reagent systems for many tests are known and may be selected according to the specific assay protocol.
The specific embodiments are added to illustrate the practice invention and are not intended to limit the scope of the invention.
A fresh human semen sample in a cup is obtained from a donor. The sample is allowed to liquefy for about 30 minutes at room temperature. An aliquot is removed for counting. The count is 27×106 cells per ml. A series of dilutions is made using phosphate buffered saline, pH 7.4 (PBS). The dilutions are 1:2; 1:4; 1:8; and 1:16 in PBS. One hundred microliters of each dilution is pipetted into the well of a 1.2 micron pore size 96 well membrane plate where the wells have a capacity of about 400 ul and the membrane filter area is 0.28 cm2 Vacuum is applied from a water stream for about 60 seconds. There is virtually no detectable separation of the 1:2 dilution; the seminal plasma is readily separated from the other dilutions.
A fresh semen sample in a cup is obtained from a donor. The sample is allowed to liquefy for about 30 minutes room temperature. An aliquot is removed for counting. Cell number is determined to be 78×106 cells/ml A series of semen dilutions are prepared using phosphate-buffered saline, pH 7.4 (PBS consists of 1440 mg/L KH2 PO4 +90 g/L NaCl +7950 mg/L Na2 HPO4 in water, available from Whittaker M.A. Bioproducts). One hundred ul of each dilution is pipetted into the well of a 1.2 μm membrane plate from Pall Corp. (product no. SM120L). Controls are no semen, PBS alone. The plate is placed on a vacuum manifold (from Isolab).
Vacuum is applied (house vacuum) so as to remove all liquid in the wells without breaking the membrane. About 400 ul PBS is added to each well with the vacuum on. This washing method is repeated. When all the wells are completely free of liquid, the vacuum is turned off. The bottom of the wells are blotted with absorbent paper. Then 200 ul freshly prepared substrate-detergent [2.3 mM N-benzoyl-dl-arginine p-nitroanilide hydrochloride (BAPA), 10% dimethyl sulfoxide, 0.1% Triton-X 100 (octyl phenoxyl polyethoxy ethanol), 0.55 M Hepes (N-[2-hydroxyethyl]-piperazine -N'-[2-ethanesulfonic acid]) and 0.055 M NaCl, pH 8.0) is added to each well. After 180 minutes incubation at room temperature, 10 ul of 500 mM benzamidine solution is added to each well. The contents of each well are removed and read in a spectrophotometer at 405 nm wavelength. The results are shown below:
______________________________________
Semen Number of Optical Density
Acrosin
Dilution
Spermatozoa at 405 nm Activity*
______________________________________
1:10 7.8 × 10.sup.5
0.379 57 ulU/10.sup.6 sperm
1:100 7.8 × 10.sup.4
0.042 63 ulU/10.sup.6 sperm
1:1000 7.8 × 10.sup.3
0.000 --
PBS 0 0.000 --
______________________________________
*One IU of acrosin activity is defined as the amount of enzyme that
hydrolyzes 1 umol BAPA/min at 37° C. The uIU acrosin per million
spermatozoa is calculated as the difference in optical density at 410 nM
between the mean of the test assays and the control, multiplied by one
million, and divided by [the product of 9.9 mM.sup.-1 · cm.sup.-
times 180 min. times the number of sperm in millions added to each tube
divided by the total volume (1.2 ml)]. A change in absorbance of 9.9
corresponds to the hydrolysis of 1.0 umol of BAPA. For simplicity, the
following formula can be applied:
##STR1##
The presence of sperm-reactive antibodies in test antiserum is assayed on control spermatozoa. A fresh semen sample in a cup is obtained from a donor. The sample is allowed to liquefy for about 30 minutes room temperature. An aliquot is removed for counting. The cell number is determined to be 96×106 cells/ml The semen is diluted using PBS by adding 100 ul of semen to 1900 ul of PBS. Then 100 ul of the diluted semen is pipetted into the wells of a 0.22 um Durapore (product no. STGV 09610) plate from illipore. The plate is placed on a vacuum manifold (from Isolab). Vacuum is applied so as to remove all liquid in the wells. About 400 ul PBS is added to each well with the vacuum on. This washing method is repeated. When all the wells are completely free of liquid, the vacuum is turned off. The bottom of the wells are blotted with absorbant paper. Either PBS or normal (nonreactive) or test antiserum diluted 1:20 with PBS are added to the appropriate wells. The contents of each well are incubated at room temperature 10 minutes. The well contents are washed as above. Next 20 ul of goat anti-human immunoglobulin A conjugated to alkaline phosphatase (anti-IgA-AP, purchased from Cappel) is diluted by adding 5 ul to 4 ml PBS and added to the appropriate wells. This is repeated using 20 ul of goat anti-human immunoglobulin G conjugated to alkaline phosphatase (anti-IgG-AP, purchased from Cappel) diluted by adding 5 ul to 6 ml PBS and 20 ul of goat anti-human immunoglobulin M conjugated to alkaline phosphatase (anti-IgM-AP, purchased from Cappel) diluted by adding 5 ul to 5 ml PBS. The contents of the wells are incubated for 10 minutes and then washed as above. To each well is added 200 ul freshly prepared substrate. The substrate is 5 mg para-nitrophenyl phosphate dissolved in 5 ml buffer [26.2 g diethanolamine dissolved in 250 ml water, pH 9.8, with 1 ml magnesium chloride (2.03 g MgCl2 ·6H2 O in 20 ml water)]. After 15 minutes incubation, the contents of each well are removed and read in a spectrophotometer at 405 nm wavelength. The results are shown below:
______________________________________
Optical Density
Sample anti-IgA-AP
anti-IgG-AP
anti-IgM-AP
______________________________________
sperm alone
.050 (1%)* .056 (1%) .023 (1%)
normal serum
.036 (1%) .130 (2%) .187 (3%)
positive serum 1
.271 (9%) .627 (19%) .861 (23%)
positive serum 2
.718 (24%) 1.158
(51%) .670 (22%)
______________________________________
*Values in parentheses correspond to percent binding values obtained with
the Immunobead Test (BioRad).
A fresh semen sample in a cup is obtained from a donor The sample is allowed to liquify for about 30 min. room temperature. An aliquot is diluted 1:50 with PBS (100 ul semen +4900 ul PBS). Then 200 ul of the diluted semen is pipetted into the wells of a 1.2 um membrane plate from Pall Corp. (product no. SM120L). The plate is placed on a vacuum manifold (from Isolab). Vacuum is applied so as to remove all liquid in the wells and collect individual filtrates into a 96-multiwell plastic plate positioned immediately beneath the membrane plate. Then 60 ul of 1.8% (w/v) ZnSO4 ·7H2 O are added to each well. The plate is gently shaken to mix. 40 ul of 0.1 M NaOH are added and the plate is gently shaken to mix. The plate and contents are incubated 15 min. at room temperature. The contents are transferred to a second 1.2 um membrane plate and vacuum is applied so as to remove all liquid in the wells and collect individual filtrates into a 96-multiwell plastic plate positioned immediately beneath the membrane plate. A 250 ul portion of each filtrate is transferred to glass test tubes with glass stoppers. For controls, 250 ul of each working fructose standard which are 0.28 mM and 0.14 mM fructose diluted up fresh from a frozen stored stock of 2.8 mM fructose are used with 250 ul distilled water as a reagent blank. To each glass test tube 250 ul indol reagent are added. The indol reagent is made by first dissolving 200 mg benzoic acid in 100 ml water at 60° C., then adding 25 mg indol and filtering the solution before stirring at 4° C. Then 2.5 ml concentrated HCl are added to each test tube. The test tubes are stoppered and incubated 20 min. at 50° C. They are cooled in ice water to room temperature and the O.D. is read at 470 nm.
The fructose concentration (mmol/L) in seminal plasma is calculated according to the equation:
[fructose](mmol/L)=OD.sub.470 ×F×75
where F =mean fructose standard factor according to the formula: ##EQU1## where s1 and s2 are the mean optical density readings for the 0.14 mM and 0.28 mM fructose standards, respectively; 75 is the dilution factor of seminal plasma.
The presence of spermreactive antibodies in test antiserum is assayed on control spermatozoa. A fresh semen sample in a cup is obtained from a donor. The sample is allowed to liquify for about 30 minutes room temperature. An aliquot is removed from counting. The cell number is determined to be 287×106 cells/ml The semen is diluted using 0.5% casein in PBS by adding 100 ul of semen to 500 ul of 0.5% casein in PBS. Then 25 ul of the diluted semen is pipetted into the wells of a 0.45 um Loprodyne plate (product number SM3000L5) from Pall. Then 25 ul of 0.5% casein in PBS or normal (nonreactive) or test antiserum each diluted 1:2 with 0.5% casein in PBS are added to the appropriate wells. The contents of each well are incubated at 37° C. 1 hour. The plate is placed on a vacuum manifold (from Isolab). About 400 ul of 0.5% casein in PBS is added to each well. Vacuum is applied so as to remove all liquid in the wells. The vacuum is turned off as soon as the wells are emptied. This washing method is repeated twice. Next a mixture of equal amounts of goat anti-human immunoglobulin A conjugated to peroxidase and goat anti-human immunoglobulin G conjugated to peroxidase (both from OEM Concepts Inc.) is diluted by adding 10 ul to 2.5 ml 0.5% casein in PBS. Then 50 ul of this diluted mixture is added to each well. The contents of the wells are incubated 30 minutes 37° C. and then washed as above. To each well is added 75 ul ABTS (2,2'-aziino-di-[3-ethylbenzthiazoline sulfonate (6)]) 1 component substrate (product number 50-66-00) from Kirkegaard and Perry. After 5 minutes incubation room temperature, the contents of each well are removed and read in a spectrophotometer at 405 nm wavelength. The results are shown below:
______________________________________
Optical Density
Sample Reading Reading Mean Result*
______________________________________
sperm alone
.00 .00 .00 Negative
normal serum
.10 .11 .105 Negative
positive serum 1
.21 .21 .21 Positive
positive serum 2
.31 .20 .255 Positive
______________________________________
*With respect to the presence or absence of spermreactive antibodies
Claims (7)
1. In an assay for antisperm antibodies the method of separating seminal plasma from semen which comprises applying semen to a membrane having an average pore diameter of 0.15-3.0 μm which only allows the seminal plasma to pass through the membrane surface while retaining particulates on said membrane.
2. A method for the determination of sperm antibodies which comprises separating seminal plasma from particulates by means of a membrane having an average pore diameter of 0.15-3.0 μm which only allows the seminal plasma to pass through the membrane surface while retaining particulates on said membrane, contacting the separated particulates on said membrane with an anti-immunoprotein labeled with an enzyme, adding an enzyme substrate and determining the amount of antibody.
3. A method as defined in claim 2, wherein the amount of antibody is determined spectrophotometrically.
4. A method as defined in claim 2, wherein the enzyme is alkaline phosphatase.
5. A method as defined in claim 2, wherein the enzyme is peroxidase.
6. A method as defined in claim 4, wherein the separation is carried out with a vacuum.
7. A method as defined in claim 4, wherein the anti-immunoprotein is an immunoglobulin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/685,439 US5185246A (en) | 1989-04-17 | 1991-04-15 | Method for semen analysis employing membrane separation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/339,505 US5028526A (en) | 1989-04-17 | 1989-04-17 | Method for semen analysis |
| US07/685,439 US5185246A (en) | 1989-04-17 | 1991-04-15 | Method for semen analysis employing membrane separation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/339,505 Continuation-In-Part US5028526A (en) | 1989-04-17 | 1989-04-17 | Method for semen analysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5185246A true US5185246A (en) | 1993-02-09 |
Family
ID=26991659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/685,439 Expired - Fee Related US5185246A (en) | 1989-04-17 | 1991-04-15 | Method for semen analysis employing membrane separation |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US5185246A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834225A (en) * | 1997-01-15 | 1998-11-10 | Board Of Trustees Operating Michigan State University | Method, device and test kit for capacitation of sperm |
| US5935800A (en) * | 1994-10-31 | 1999-08-10 | Beth Israel Deaconess Medical Center | Assays and kits for determining male fertility |
| US5958714A (en) * | 1996-10-02 | 1999-09-28 | Safety Associates, Inc. | Test kits for determining at least two specific analytes in foods and other complex matrices |
| US6129214A (en) * | 1997-12-19 | 2000-10-10 | Bar-Ami; Shalom | Sperm strainer system |
| WO2001017443A1 (en) | 1999-09-09 | 2001-03-15 | Tamar Tennenbaum | A method and device for artificial insemination |
| US6357596B1 (en) | 1997-12-19 | 2002-03-19 | Machelle Seibel | Sperm strainer system |
| US6391654B1 (en) * | 1998-08-14 | 2002-05-21 | Genosis Limited | Separation and detection of spermatozoa |
| WO2008104042A1 (en) * | 2007-02-28 | 2008-09-04 | Ferraz Pedrazzi Cesar Augusto | Semen manipulation process |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3909363A (en) * | 1972-09-11 | 1975-09-30 | Investors In Ventures Inc | Method for testing body fluids such as semen |
| US5021244A (en) * | 1988-12-06 | 1991-06-04 | Cytogam, Inc. | Sex-associated membrane antibodies and their use for increasing the probability that offspring will be of a desired sex |
-
1991
- 1991-04-15 US US07/685,439 patent/US5185246A/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3909363A (en) * | 1972-09-11 | 1975-09-30 | Investors In Ventures Inc | Method for testing body fluids such as semen |
| US5021244A (en) * | 1988-12-06 | 1991-06-04 | Cytogam, Inc. | Sex-associated membrane antibodies and their use for increasing the probability that offspring will be of a desired sex |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5935800A (en) * | 1994-10-31 | 1999-08-10 | Beth Israel Deaconess Medical Center | Assays and kits for determining male fertility |
| US5958714A (en) * | 1996-10-02 | 1999-09-28 | Safety Associates, Inc. | Test kits for determining at least two specific analytes in foods and other complex matrices |
| US5834225A (en) * | 1997-01-15 | 1998-11-10 | Board Of Trustees Operating Michigan State University | Method, device and test kit for capacitation of sperm |
| US6129214A (en) * | 1997-12-19 | 2000-10-10 | Bar-Ami; Shalom | Sperm strainer system |
| US6357596B1 (en) | 1997-12-19 | 2002-03-19 | Machelle Seibel | Sperm strainer system |
| US6391654B1 (en) * | 1998-08-14 | 2002-05-21 | Genosis Limited | Separation and detection of spermatozoa |
| WO2001017443A1 (en) | 1999-09-09 | 2001-03-15 | Tamar Tennenbaum | A method and device for artificial insemination |
| WO2008104042A1 (en) * | 2007-02-28 | 2008-09-04 | Ferraz Pedrazzi Cesar Augusto | Semen manipulation process |
| US20100099075A1 (en) * | 2007-02-28 | 2010-04-22 | Cesar Augusto Ferraz Pedrazzi | Semen manipulation process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3457324B2 (en) | Rapid immunoassay for testing antibodies or antigens, including simultaneous sample extraction and immunogenic reactions | |
| US4407943A (en) | Immobilized antibody or antigen for immunoassay | |
| US6303389B1 (en) | Rapid flow-through binding assay apparatus and method therefor | |
| EP0444302B1 (en) | Method of immunoassay including deactivation of endogenous alkaline phosphatase | |
| AU666821B2 (en) | Analyte detection device and process | |
| DK1824991T3 (en) | Device and method for the detection of analytes | |
| EP0239318B1 (en) | Assay employing binding pair members on particles and on a filter or membrane | |
| US4965187A (en) | Method and apparatus for assaying whole blood | |
| AU682663B2 (en) | Solid phase immunological assay | |
| US20020127737A1 (en) | Testing device for determining analytes in a liquid dairy product | |
| JP2002526774A (en) | Assay using loss of porosity to prevent migration | |
| JPH0750114B2 (en) | Analysis method using immunoassay instrument | |
| US4939096A (en) | Method and apparatus for assaying whole blood | |
| US5185246A (en) | Method for semen analysis employing membrane separation | |
| US5028526A (en) | Method for semen analysis | |
| US6413778B1 (en) | Methods for the detection and identification of crystals in biological fluids | |
| EP0328388A2 (en) | Wash solution, test kit and method for the determination of an immunological ligand | |
| IE901081L (en) | Enzymatic assay kit and method applicable to whole cells | |
| WO1986005591A1 (en) | Method for the immunological determination of a biological substance in a sample | |
| US5314803A (en) | Process and test carrier for the determination of an enzyme from an isoenzyme mixture | |
| EP0756173A1 (en) | Reagent for detecting substances and method for diagnosing rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20010209 |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |